@Parko5 The EGM meeting is now available to replay with captions at the side. Most of the CEOs garbled audio was magically picked up.
Regarding the pace of commercialisation, perhaps the CEO is a cautious steady-as-she-goes scientific personality, while David is obviously cracking the whip. 'It's worth crashing through'.
The discussion to me sounded promising: Their testing product is out-of-the-box being well received and experimented with in novels settings - even for transplant patients for early indications of rejection. This looks like crowd-sourcing research and product feedback, developing industry and academic familiarity with the technology, and would presumably lead to cross-pollination of ideas and use-cases and maybe even business relationships centered on 'goals'.